Rosetta forms diagnostics pact for lung and mesothelioma cancers:
This article was originally published in Clinica
Israel's Rosetta Genomics has linked up with the NYU Medical Center in the US to develop a line of early detection diagnostic products for lung and mesothelioma cancers. The test will mainly target the 45 million population in the US that is at increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibres, said the Rehovot-based firm. It will use Rosetta's proprietary protocol to extract microRNAs from a simple blood draw. "MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers," said partner Dr Harvey Pass, of the New York-based medical centre.